CEO Baldwin Amanda sold 451,837 shares of OLPX at $1.17; stock down 29.8% from 52-week high, down 19.9% in 30 days.
CEO Baldwin Amanda sold 451,837 shares (4.7% of pre-transaction holdings) on 2026-03-13 at $1.17, reducing her position from 9.58M to 9.13M shares. The sale occurred as OLPX traded 29.8% below its 52-week high of $1.78 and has declined 19.9% over the preceding 30 days. Notably, Baldwin's cross-ticker track record shows a 100.00% well-timed rate on her prior sell (90-day return -28.1%), and her most recent prior trade at OLPX on 2024-12-11 was a sell that also proved well-timed (90d return -28.1%). The company is currently unprofitable on a full-year basis despite generating $114.6M in quarterly revenue, with minimal annual revenue growth of +0.1%. The timing of this CEO sale in a context of sustained stock weakness and the insider's demonstrated pattern of well-timed sells at this ticker warrants monitoring of company fundamentals.
Egan buys 10,000 OLPX shares at $1.34; stock now $1.27, down 51.5% from 52-week high
Kenneth F. Egan purchased 10,000 shares of OLAPLEX at $1.34 on 2025-03-14, representing his first position in the stock. The transaction occurs as OLPX trades at $1.27, approximately 7 cents below the purchase price, and has declined 51.5% from its 52-week high of $2.62. The company reported net income of $14.8M on revenue of $119.1M in the latest quarter, though annual revenue contracted 7.8% year-over-year, suggesting operational challenges. The elevated P/E of 42.33 despite negative revenue growth and a market cap of $844.1M presents an unusual valuation backdrop for a new insider position establishment.
CEO Amanda Baldwin sells 382,555 OLPX shares at $2.10; holds 2.82M post-transaction amid 30d +20.0% bounce from lows.
CEO Amanda Baldwin sold 382,555 shares of OLAPLEX at $2.10 on 2024-12-11, reducing her holdings from 3.21M to 2.82M shares (-11.9% of pre-transaction position). The stock has rebounded +20.0% over 30 days but remains -19.8% from its 52-week high of $2.62. Broader context shows the company faces significant headwinds: annual revenue declined -34.9% year-over-year despite latest quarterly revenue of $119.1M and net income of $14.8M, and the stock trades at a P/E of 35.00. This sale occurs without a discernible pattern from the CEO's limited cross-ticker transaction history (one prior buy with +23.7% 30-day return), leaving the transaction's timing and motivation opaque against the current price momentum and steep valuation multiple.
Director Bilbrey buys 76,825 shares in 2 transactions for $134,695.03 as OLPX falls -33.2% from 52-week high
Director John P Bilbrey purchased 76,825 shares across 2 separate transactions on 2024-11-15 and 2024-11-18 at an average price of $1.75, increasing his stake by 31.8% to 318,418 shares total. This buying occurred amid significant price weakness: OLPX is trading -33.2% from its 52-week high and -15.9% over the past 30 days. Bilbrey's cross-ticker track record shows 4 prior open-market buys with an average 90-day return of -17.5% and a 90-day win rate of 25.00%, while his 4 prior trades specifically at OLPX produced mixed results with only 1 of 4 well-timed at the 90-day mark. The company faces revenue headwinds with -34.9% annual revenue decline year-over-year, though current fundamentals show positive net income of $14.8M on $119.1M quarterly revenue. The timing of this purchase during a sharp drawdown and against a backdrop of declining revenues warrants monitoring of whether this reflects genuine confidence or merely opportunistic accumulation at depressed levels.
CEO Baldwin Amanda purchased 43,000 shares of OLPX at $1.73 on 2024-11-08 for $74,390.00; stock down -25.8% in 30 days, -35.1% from 52-week high.
CEO Amanda Baldwin purchased 43,000 shares at $1.73, expanding her holdings to 3,205,055 shares post-transaction. The purchase occurs amid significant recent price weakness: the stock is down -25.8% over the past 30 days and -35.1% from its 52-week high of $2.62, suggesting the CEO is buying into a materially depressed price. However, fundamental context tempers the signal: annual revenue has contracted -34.9% year-over-year, net income remains modest at $14.8M relative to the $1.1B market cap, and the P/E of 28.33 remains elevated despite current valuation levels. The insider purchase size (+1.4% relative to pre-transaction holdings) represents a modest accumulation rather than a dramatic confidence statement, warranting examination of whether broader CEO or board activity exists and monitoring of whether near-term operational trends can stabilize the revenue decline.
Director Bilbrey bought 183,493 shares of OLPX at $2.05 on 2024-08-19, raising stake 315.8% to 241,593 shares
Director John P. Bilbrey purchased 183,493 shares of OLAPLEX at $2.05, a substantial open-market accumulation that increased his holdings from 58,100 to 241,593 shares (+315.8%). His cross-ticker track record on prior buys shows an average 90-day return of -18.5% with a 33.33% win rate, suggesting limited predictive accuracy. At OLPX specifically, his three prior buys (2023-08-14, 2023-08-15, 2023-09-15) yielded mixed results: only one achieved a positive 90-day outcome, while two posted declines of -34.2% and -34.3%. The current stock price of $2.19 stands 20.4% below its 52-week high and has recently gained 14.1% over 30 days and 51.0% over 90 days, though the company's revenue contracted 34.9% year-over-year despite positive net income of $5.8M. The prior OLPX buy patterns and weaker cross-ticker timing history provide limited evidence that this accumulation reflects a high-conviction contrarian signal.
Add OLPX to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
